Sarepta Therapeutics (SRPT) Cash from Operations Growth (3y) (2013 - 2026)

Sarepta Therapeutics (SRPT) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Sarepta Therapeutics 1.69 Bn 1.28 Bn 622.04 Mn 1.08%

Historic Data

Download Data
DateValue
Mar 31, 2026 1.08%
Dec 31, 2025 50.67%
Sep 30, 2025 39.22%
Jun 30, 2025 80.81%
Mar 31, 2025 -79.32%
Dec 31, 2024 72.56%
Sep 30, 2024 17.15%
Jun 30, 2024 28.80%
Mar 31, 2024 -10.30%
Dec 31, 2023 32.09%
Sep 30, 2023 21.62%
Jun 30, 2023 -4.34%
Mar 31, 2023 -32.64%
Dec 31, 2022 17.38%
Sep 30, 2022 1.23%
Jun 30, 2022 5.43%
Mar 31, 2022 11.55%
Dec 31, 2021 37.89%
Sep 30, 2021 -3.14%
Jun 30, 2021 2.36%